Company profile: Rallybio
1.1 - Company Overview
Company description
- Provider of biotechnological R&D services developing investigational therapies, including RLYB212 to prevent HPA-1a alloimmunization in expectant mothers at higher risk of FNAIT; RLYB116, a self-delivered C5-targeting antibody mimetic; RLYB114, a C5-targeted Affibody for ophthalmic diseases; RLYB331, a monoclonal antibody targeting MTP-2 for iron overload; and an ENPP1 inhibitor program for hypophosphatasia.
Products and services
- ENPP1 Program: A small-molecule inhibitor of ENPP1 developed to treat hypophosphatasia by reducing inorganic pyrophosphate levels to promote bone mineralization
- RLYB114: An affibody-based C5-targeted molecule for ophthalmic diseases, administered intravitreally to inhibit complement activation and reduce ocular inflammation
- RLYB116: An autoinjector-enabled antibody mimetic fusion protein targeting C5, architected for self-delivery to treat diseases caused by complement dysregulation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Rallybio
Larimar Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology treatments for complex rare diseases, including CTI-1601, a recombinant fusion protein designed to deliver human frataxin into mitochondria for patients with Friedreich’s ataxia (in Phase 1 clinical trials), and a proprietary protein replacement therapy platform intended to deliver missing proteins inside cells to treat rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Larimar Therapeutics company profile →
Edgewise Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development of small-molecule therapies, including EDG-5506 to protect muscle fibers in rare skeletal muscle disorders (Duchenne and Becker muscular dystrophies), and EDG-7500, an oral, selective cardiac sarcomere modulator for hypertrophic cardiomyopathy and other diseases of cardiac diastolic dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Edgewise Therapeutics company profile →
eTherapeutics
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development solutions using proprietary computational systems to analyze and predict medicine–cell interactions, optimizing efficacy and minimal side effects. Includes HepNet™ computational biology and GalOmic™ RNAi platforms, with candidates ETX-312 (MASH), ETX-407 (dAMD), ETX-148 (haemophilia), and ETX-291 (cardiometabolic).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full eTherapeutics company profile →
Bioverativ
HQ: United States
Website
- Description: Provider of innovative therapies for hemophilia and other rare blood disorders through world-class research, development and commercialization by a global biotechnology company dedicated to transforming lives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bioverativ company profile →
Actio Biosciences
HQ: United States
Website
- Description: Provider of rare disease drug discovery and development, with a small molecule TRPV4 program for Charcot-Marie-Tooth disease type 2C and serious bone diseases; a proprietary Rare Disease Target Atlas for target identification and function; a partnership with The Jackson Laboratory to create transgenic models for target evaluation and phenotype analysis; and upcoming programs for genetic epilepsies and genetic skin conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Actio Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Rallybio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Rallybio
2.2 - Growth funds investing in similar companies to Rallybio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Rallybio
4.2 - Public trading comparable groups for Rallybio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →